From Wikipedia, the free encyclopedia
Jump to: navigation, search

RG7314 is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2014, it is in phase II clinical trials for this indication.[2]

See also[edit]